Analysts expect revenue increase Biocartis

Tomorrow Biocartis will publish its past quarters results. Over the current book year the company from Malines (Mechelen)'s total revenue could be around 58.07 million euros (consensus estimates). This is quite more than 2021's revenue of 43.13 million euros.

Historical revenues and results Biocartis plus estimates 2021

The analysts expect for 2021 a net loss of 74 million euros. For this year most of the analysts expect a loss per share of 1.27 euros. The PE-ratio therefore is -3.28.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is an attractive 2.63 percent.

Latest estimates around 6 euros

Based on the current number of shares Biocartis 's market capitalization equals 234.55 million euros. -12

Price data Biocartis 2007-2021

At 10.33 the stock trades 2.28 percent higher at 4.16 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.